openPR Logo
Press release

Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Poised for Remarkable Growth, Reaching USD 370 Billion by 2033 | FMI

04-28-2025 09:08 AM CET | Health & Medicine

Press release from: Future Market Insights Inc

Fuchs Endothelial Corneal Dystrophy (FECD) Market

Fuchs Endothelial Corneal Dystrophy (FECD) Market

Future Market Insights (FMI) has unveiled a compelling new report forecasting significant expansion in the global fuchs endothelial corneal dystrophy market. The report highlights a surge in market value from USD 180 billion in 2023 to an anticipated USD 370 billion by 2033, marking a robust Compound Annual Growth Rate (CAGR) of 7.5% over the forecast period.

Several pivotal factors are driving this impressive market growth. The increasing prevalence of Fuchs' endothelial corneal dystrophy is generating a higher demand for advanced treatment options. As the global population ages, the incidence of age-related diseases like FECD is rising, further accelerating the need for effective healthcare solutions.

Stay Updated with Market Movements: Get Your Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d3136323433

The demographic shift towards an aging population is a significant contributor to the market's expansion. With the number of elderly individuals increasing, the demand for treatments addressing age-related eye conditions is expected to climb. Additionally, heightened awareness efforts by governmental and private organizations about eye disorders and the promotion of corneal donation are set to bolster market growth.

The surge in research focusing on cellular treatment techniques is also expected to create lucrative opportunities within the FECD market. The growing emphasis on comprehensive eye care services is further fueling the demand for innovative solutions.
FMI's report provides an in-depth analysis of the market dynamics, competitive landscape, and key trends shaping the future of the global FECD market. It offers actionable insights for industry stakeholders, equipping them with the intelligence needed to make informed decisions and seize emerging opportunities.

Key Takeaways from the Market Study

• FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033.

• The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of USD 180 Billion.

• The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of USD 370 Billion.

• As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023-2033.

• North America is expected is expected to grow at a CAGR of 7.4% in the assessment period 2023-2033.

• Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023-2033.

• The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market in the forecast period 2023-2033.

"Asia-Pacific is predicted to rise over the projected period of 2023-2033 due to increased R&D activities, increased investment in the healthcare industry, and more government assistance," says an analyst at FMI

Explore the High Demand for Fuchs Endothelial Corneal Dystrophy: Our Full Report Provides a Detailed Look at Emerging Trends! https://www.futuremarketinsights.com/reports/fuchs-endothelial-corneal-dystrophy-fecd-market

Market Competition

Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are

• Kowa Pharmaceuticals
• Trefoil Therapeutics
• Alcon
• Emmecell
• Santen
• AJL Ophthalmic SA
• Massachusetts Eye and Ear
• KeraMed, Inc.
• Presbia Plc

In May 2022, SEGLENTIS® C-IV is now available for purchase through Kowa Pharmaceuticals America, Inc.

Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey

By Treatment:
• Phototherapeutic Keratectomy
• Amniotic Membrane Transplants
• Anterior Stromal Puncture
• Conjunctival Flaps

By Diagnosis:
• Slit-lamp Examination
• Molecular Genetic Tests
• Pachymetry

By End User:
• Hospitals
• ASCs
• Others

By Region:
• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific
• Middle East & Africa (MEA)

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Poised for Remarkable Growth, Reaching USD 370 Billion by 2033 | FMI here

News-ID: 3989817 • Views:

More Releases from Future Market Insights Inc

Powder Induction and Dispersion Systems Market to Touch USD 10.0 Billion by 2036 as Industrial Processing Scaling Accelerates Global Manufacturing Automation
Powder Induction and Dispersion Systems Market to Touch USD 10.0 Billion by 2036 …
The global powder induction and dispersion systems market is transitioning into a highly standardized infrastructure tier. Driven by industrial mandates for lump-free, high-shear dry ingredient incorporation and dust elimination across large-scale mixing lines, the marketplace is shifting cleanly away from open vessels and manual labor, according to latest insights by Future Market Insights. The overall industry is estimated to grow from USD 2.6 billion in 2026 to USD 10.0 billion
Plant-Based Egg Bites Market to Cross USD 508.9 Million by 2036 as Frozen Breakfast Convenience and Egg Supply Risks Drive Category Growth
Plant-Based Egg Bites Market to Cross USD 508.9 Million by 2036 as Frozen Breakf …
The global plant-based egg bites market is rapidly transitioning from a specialized vegan novelty into a critical risk-management and convenience category for retailers and foodservice kitchens alike. Driven by extreme egg-price volatility, avian influenza (HPAI) supply shocks, and consumer demand for cholesterol-free morning options, pre-portioned egg alternatives are securing massive mainstream adoption. According to insights by Future Market Insights, the global industry is projected to rise from USD 240.0 million
Fermented Legume Protein Market to Cross USD 3.6 Billion by 2036 as Next-Gen Plant Proteins Move Beyond Heavy Extrusion and
Fermented Legume Protein Market to Cross USD 3.6 Billion by 2036 as Next-Gen Pla …
The global fermented legume protein market is experiencing a significant structural shift, emerging as a clean-label correction to the first wave of highly processed plant-based meat alternatives. Driven by consumers demanding shorter ingredient lists, better digestibility, and superior flavor profiles, food manufacturers are turning to microbial fermentation to overhaul raw pulse bases. According to comprehensive industry insights by Future Market Insights, the global market is projected to reach USD 1.5
Cultured Wheat-Based Mold Inhibitors Market to Hit USD 264.6 Million by 2036 as Industrial Bakeries Phase Out Synthetic Propionates
Cultured Wheat-Based Mold Inhibitors Market to Hit USD 264.6 Million by 2036 as …
The global cultured wheat-based mold inhibitors for bakery market is entering a crucial scale-up phase. As commercial food brands face tightening retail compliance screens and deep consumer pushback against synthetic salts, standard preservatives like calcium propionate are increasingly being dropped in favor of fermentation-derived, flour-native solutions. According to comprehensive industry insights by Future Market Insights, the global market is projected to reach USD 128.4 million in 2026 and expand to

All 5 Releases


More Releases for FECD

Fuchs Endothelial Corneal Dystrophy Market Shows Strong Growth Potential with Em …
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2036" report offers an in-depth understanding of Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the FECD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Key Fuchs Endothelial Corneal Dystrophy Companies in the market include - Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye
Fuchs Endothelial Corneal Dystrophy (FECD) Market to Grow at a CAGR of 6.1%
Pune, India - Exactitude Consultancy: The global Fuchs Endothelial Corneal Dystrophy (FECD) Market is projected to grow at a CAGR of 6.1% during the forecast period. Rising prevalence of corneal endothelial dysfunction among older adults, increasing cataract surgery volumes, and technological advancements in corneal transplantation are major contributors to market growth. Emerging regenerative cell therapies and improved imaging capabilities further expand the treatment landscape. Download Full PDF Sample Copy of Market
Fuchs Endothelial Corneal Dystrophy Market Outlook 2024-2034: From Standard of C …
The US accounts for the largest market size of Fuchs Endothelial Corneal Dystrophy in 2023, i.e. nearly USD 394 million, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. In the 7MM, the market mainly consisted of Standard of care (Hyperosmotic sodium chloride, Steroids, etc.), which generated nearly USD 850 million in 2023. Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive hereditary disease that affects the endothelial
Fuchs Endothelial Corneal Dystrophy Pipeline Fuels Robust Market Growth Through …
The Fuchs Endothelial Corneal Dystrophy (FECD) treatment landscape is poised for significant advancement, driven by innovative regenerative therapies and targeted approaches from key industry players such as Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, and Design Therapeutics. DelveInsight's "Fuchs Endothelial Corneal Dystrophy - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides a comprehensive analysis of the evolving FECD therapeutic landscape, featuring detailed profiles of Fuchs endothelial corneal dystrophy companies such as Kowa Pharmaceuticals (TYO:
Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Size, Share, Forecast 2 …
The Global Fuchs Endothelial Corneal Dystrophy Market is expected to grow from USD 170 billion in 2022 to USD 360 billion by 2032, at a CAGR of 7.7% during the forecast period 2022-2032. Request To Download Free Sample copy of the report @ https://www.sphericalinsights.com/request-sample/ Comprehensive historical analysis of global market for Fuchs Endothelial Corneal Dystrophy (FECD) has thoroughly analyzed in this report. It offers data and insights from 2019-2022, and provides extensive
Fuchs Endothelial Corneal Dystrophy (FECD) Market is expected to garner a market …
The global Fuchs Endothelial Corneal Dystrophy (FECD) Market had a market value of US$ 180 Billion in 2023 and is expected to reach a market value of US$ 370 Billion by 2023-2033, at a CAGR of 7.5%. The growing global elderly population, as well as increased awareness of eye diseases and corneal donation, are expected to boost the market. Furthermore, increased research interest in cellular treatment techniques is expected to